Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
J Matern Fetal Neonatal Med ; 32(1): 125-128, 2019 Jan.
Article in English | MEDLINE | ID: mdl-28868940

ABSTRACT

PURPOSE: Urinary tract infection (UTI) is defined as a common bacterial infection that can lead to significant morbidity such as stricture, fistula, abscess formation, bacteremia, sepsis, pyelonephritis, and kidney dysfunction with a mortality rates reported of 1% in men and 3% in women because of development of pyelonephritis. UTIs are more common in women and the 33% of them require antimicrobials treatment for at least one episode by the age of 24 years. UTIs are the most common infections observed during pregnancy and up to 30% of mothers with not treated asymptomatic bacteriuria may develop acute pyelonephritis which consequently can be associated to adverse maternal and fetal outcomes. All bacteriuria in pregnancy should be treated with antimicrobial treatments being safe for both the mother and the fetus. Approximately one every four women receives prescription of antibiotic treatment during pregnancy, nearly 80% of all the prescription medications during gestation. The use of fosfomycin to treat cystitis in pregnancy generally considered safe and effective. Even though use on antibiotics for urinary tract infections is considered generally safe for the fetus and mothers, this opinion is not based on specific studies monitoring the relationship of among urinary infections, consumption of antibiotics, and pregnancy outcomes. MATERIALS AND METHODS: On this basis we decided to analyze data from the database of our multicenter study PHYTOVIGGEST, reporting data from 5362 pregnancies, focusing on use of fosfomycin. Principal outcomes of pregnancy in women treated with fosfomycin were taken into consideration. RESULTS: Women who have been treated with urinary antibiotics during the pregnancy were 183. With respect to the total number of pregnancies of our sample, these women represented the percentage of 3.49% (187/5362). Analysis of different outcomes of pregnancy such as gestational age, neonatal weight, and neonatal Apgar index did not show any significant difference. At the same time, analysis of data of pregnancy complicancies (such as urgent cesarean delivery, use of general anesthesia, need to induce labor) did not show any difference in women taking fosfomycin during pregnancy and those not taking it. CONCLUSIONS: Our data, based on a large number of pregnancies, confirm the safety use of fosfomycin use in pregnancy.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Fosfomycin/therapeutic use , Pregnancy Complications, Infectious/drug therapy , Pregnancy Outcome/epidemiology , Urinary Tract Infections/drug therapy , Adult , Female , Humans , Italy/epidemiology , Pregnancy
2.
Clin Ter ; 169(6): e277-e280, 2018.
Article in English | MEDLINE | ID: mdl-30554248

ABSTRACT

OBJECTIVES: Port-a-cath catheterization is often required for those patients who need long-term therapies (malnutrition, neoplasm, renal failure, other severe diseases). The use of ports for a wide range of indications is not exempt from complications. Ultrasound-guided central venous catheterization (CVC) is a safe and fast technique for the introduction of the catheter inside a central vein. This retrospective study reports our experience with US-guided CVC in patient eligible for port-a-cath implantation. MATERIALS AND METHODS: From January 2007 to March 2017, 108 CVC (out of 770 procedures), were positioned using an ultrasound guide, with the new "one-shoot technique" (group 1) and the classic Seldinger technique (group 2). RESULTS: One-shoot techniques showed a reduced operative time, in comparison to Seldinger technique, with a negligible minor complication rate. No major complication were evidenced. CONCLUSIONS: CVC is a safe procedure, although not free from complications. Ultrasonography enhances safety of the procedure by decreasing puncture attempts and complications; it is helpful in patients with vascular anatomical variations, with no visualized or palpable landmarks or for patients with coagulation disorders.


Subject(s)
Catheterization, Central Venous/methods , Ultrasonography, Interventional , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
3.
Eur Rev Med Pharmacol Sci ; 22(19): 6567-6572, 2018 10.
Article in English | MEDLINE | ID: mdl-30338829

ABSTRACT

OBJECTIVE: Myo-inositol supplementation prevents gestational diabetes (GDM) in women at risk and reduces insulin resistance in women with GDM. No data are available about its effect on glucose variability. The aim of this study was to evaluate the effects of a supplementation of myo-inositol on glucose variability in women with GDM. PATIENTS AND METHODS: Myo-inositol effect on glucose variability was studied in a pilot case-control study involving 12 consecutive pregnant women (median age 34 years, 25.0% insulin-treated) with GDM. Six women received myo-inositol 2 g plus 200 mg folic acid twice a day, the others received only folic acid. Information on side effects was collected. A continuous glucose monitoring system was wore before and at the beginning of the supplementation. Mean amplitude of glucose excursion (MAGE), standard deviation (SD) and variability coefficient were the indexes of glucose variability. RESULTS: Myo-inositol lowered glucose levels in the first days after the treatment was started. However, pre-post supplementation overall mean glucose difference was similar between groups (-4.8 vs. 5.0 mg/dL for controls and treated, respectively; p = 0.79). Pre-post differences in SD (13.7 vs. 6.0; p < 0.001), MAGE (3.5 vs.-1.5; p < 0.001) and variability coefficient (0.14 vs. 0.02; p < 0.001) were improved in myo-inositol group. No side effects were recorded. CONCLUSIONS: Myo-inositol is effective in reducing glucose variability in women with GDM. It could be a useful strategy for treating GDM.


Subject(s)
Blood Glucose/drug effects , Diabetes, Gestational/drug therapy , Dietary Supplements , Hypoglycemic Agents/therapeutic use , Inositol/therapeutic use , Adult , Biomarkers/blood , Blood Glucose/metabolism , Case-Control Studies , Diabetes, Gestational/blood , Diabetes, Gestational/diagnosis , Dietary Supplements/adverse effects , Down-Regulation , Female , Humans , Hypoglycemic Agents/adverse effects , Inositol/adverse effects , Pilot Projects , Pregnancy , Treatment Outcome
4.
Eur Rev Med Pharmacol Sci ; 22(11): 3602-3608, 2018 06.
Article in English | MEDLINE | ID: mdl-29917215

ABSTRACT

OBJECTIVE: This study aimed at evaluating the effects obtained by administering 30 mg of micronised dispersible ferric pyrophosphate plus 300 mg of alpha-lactalbumin (MDFP-AL) compared to 80 mg of ferrous gluconate (FG) in pregnant women affected by iron-deficiency anemia (IDA). PATIENTS AND METHODS: We considered eligible all second-trimester singleton pregnancies in women affected by IDA. We excluded any other disease, twin pregnancies, any other pharmacologic/nutraceutical treatments (besides folic acid) before/during pregnancy. We randomized patients in two groups: one underwent treatment with 1 tablet of MDFP-AL/day, the other one with 1 tablet of FG/day, for 30 days. We evaluated hemoglobin (Hb), ferritin, red blood cells (RBCs), serum iron, hematocrit (Hct), and side effects at baseline (T0), after 15 days (T1) and 30 days (T2). RESULTS: 50 women met the inclusion/exclusion criteria. We did not observe significant differences between the two groups for mean age, gestational age at the enrollment and parity. In MDFP-AL group, after 15 days (T1) Hb, ferritin, serum iron and Hct and were significantly improved respect to baseline (T0); after 30 days (T2), all the parameters, including RBCs, were significantly improved respect to baseline (T0). Similarly, in FG group the investigated parameters were improved both after 15 (T1) and 30 days (T2) respect to baseline (T0), although less in percentage terms respect to MDFP-AL group. The side effects rate was 24% in FG group, whereas MDFP-AL group did not show any significant side effect. CONCLUSIONS: Overall, MDFP-AL is more effective and safe than FG for the treatment of IDA in pregnant women.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Diphosphates/therapeutic use , Iron/therapeutic use , Lactalbumin/therapeutic use , Adult , Anemia, Iron-Deficiency/pathology , Diphosphates/chemistry , Double-Blind Method , Drug Compounding , Female , Ferrous Compounds/therapeutic use , Gestational Age , Humans , Iron/chemistry , Lactalbumin/chemistry , Pregnancy , Prospective Studies , Young Adult
5.
Am J Obstet Gynecol ; 219(3): 300.e1-300.e6, 2018 09.
Article in English | MEDLINE | ID: mdl-29859136

ABSTRACT

BACKGROUND: Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Insulin sensitizing substances such as myo-inositol have been considered for the prevention of gestational diabetes mellitus and related complications. OBJECTIVE: Because previous studies failed to show a clear reduction of gestational diabetes mellitus complications, the aim of this study was to evaluate clinical and metabolic outcomes in women who are at risk for gestational diabetes mellitus supplemented with myo-inositol since the first trimester. STUDY DESIGN: A secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled) in which women who were at risk for gestational diabetes mellitus (a parent with type 2 diabetes mellitus, obese, or overweight) were supplemented with myo-inositol (4 g/d) throughout pregnancy. Main measures were the rate of adverse clinical outcomes: macrosomia (birthweight, ≥4000 g), large-for-gestational-age babies (fetal growth, ≥90 percentile), fetal growth restriction (fetal growth, ≤3 percentile), preterm birth (delivery before week 37 since the last menstruation), gestational hypertension, and gestational diabetes mellitus. RESULTS: A significant reduction was observed for preterm birth (10/291 [3.4%] vs 23/304 [7.6%]; P=.03), macrosomia (6/291 [2.1%] vs 16/304 [5.3%]; P=.04), Large-for-gestational-age babies (14/291 [4.8%] vs 27/304 [8.9%]; P=.04) with only a trend to significance for gestational hypertension (4/291 [1.4%] vs 12/304 [3.9%]; P=.07). Gestational diabetes mellitus diagnosis was also decreased when compared with the control group (32/291 [11.0%] vs 77/304 [25.3%]; P<.001). At univariate logistic regression analysis, myo-inositol treatment reduced the risk for preterm birth (odds ratio, 0.44; 95% confidence interval, 0.20-0.93), macrosomia (odds ratio, 0.38; 95% confidence interval, 0.14-0.98), and gestational diabetes mellitus diagnosis (odds ratio, 0.36; 95% confidence interval, 0.23-0.57). CONCLUSION: Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus.


Subject(s)
Diabetes, Gestational/prevention & control , Fetal Growth Retardation/epidemiology , Fetal Macrosomia/epidemiology , Hypertension, Pregnancy-Induced/epidemiology , Inositol/therapeutic use , Premature Birth/epidemiology , Vitamin B Complex/therapeutic use , Adult , Diabetes Mellitus, Type 2 , Diabetes, Gestational/epidemiology , Diabetes, Gestational/metabolism , Dietary Supplements , Female , Humans , Logistic Models , Medical History Taking , Obesity/epidemiology , Odds Ratio , Overweight/epidemiology , Pregnancy , Randomized Controlled Trials as Topic , Risk
6.
Eur Rev Med Pharmacol Sci ; 21(18): 4243-4251, 2017 Sep.
Article in English | MEDLINE | ID: mdl-29028072

ABSTRACT

OBJECTIVE: Vitamin D is a fat-soluble secosteroid hormone that regulates calcium, magnesium, and phosphate homeostasis and plays a pivotal role as antiproliferative and immunomodulatory mediator. Considering the different sources of synthesis and dietary intake as well as the pleiotropic actions in extremely diverse (micro)environments of the body, the supplementation of this Vitamin should be carefully evaluated taking into account the several pathways that it regulates. In the current brief review, we aimed to summarize the available evidence about the topic, in order to suggest the best evidence-based supplementation strategy for human reproduction, avoiding the unuseful (and sometimes hazardous) empiric supplementation. MATERIALS AND METHODS: Narrative overview, synthesizing the findings of literature retrieved from searches of computerized databases. RESULTS: Accumulating evidence from in vitro fertilization (IVF) trials suggests that fertilization rate decreases significantly with increasing levels of 25OH-D in follicular fluid; in addition, Vitamin D levels in the follicular fluid are negatively correlated to the quality of embryos and the higher values of Vitamin D are associated with lower possibility to achieve pregnancy. Both low and high Vitamin D serum concentrations decrease not only spermatozoa count, but their progressive motility as well as increase morphological abnormalities. Finally, studies in animal models found that severe hypervitaminosis D can reduce the total skeletal calcium store in embryos and may compromise the postnatal survival. CONCLUSIONS: Based on the retrieved data, we solicit to be extremely selective in deciding for Vitamin D supplementation, since its excess may play a detrimental role in fertility.


Subject(s)
Fertility , Vitamin D/metabolism , Vitamins/metabolism , Animals , Calcium/metabolism , Dietary Supplements , Female , Fertilization in Vitro , Follicular Fluid/metabolism , Humans , Pregnancy , Vitamin D/blood , Vitamin D Deficiency/complications
8.
J Matern Fetal Neonatal Med ; 30(9): 1124-1127, 2017 May.
Article in English | MEDLINE | ID: mdl-27406853

ABSTRACT

Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder characterized by maternal itching and altered liver function. Interleukin (IL)-31 is known to be involved in the pathogenesis of pruritic inflammatory skin diseases. In a three-year period, 13 women with a singleton pregnancy and a diagnosis of intrahepatic cholestasis (ICP) were enrolled together with 26 healthy single pregnant women who concluded an uncomplicated pregnancy. The inclusion criteria were itching and elevated levels of liver transaminases. Median serum levels of IL-31 were significantly higher in ICP patients than in the control group (p = 0.004). Furthermore, IL-31 values were directly dependent on liver transaminase levels.


Subject(s)
Cholestasis, Intrahepatic/blood , Interleukins/blood , Pregnancy Complications/blood , Adult , Case-Control Studies , Cholestasis, Intrahepatic/physiopathology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Linear Models , Pregnancy , Pregnancy Complications/physiopathology , Pruritus/etiology
9.
Diabetes Metab ; 42(2): 122-5, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26718735

ABSTRACT

AIM: Our objective was to compare, in a Caucasian population, the perinatal outcomes of pregnancies complicated by pregestational diabetes diagnosed in the first-trimester of pregnancy with those of pregnancies complicated by gestational diabetes. METHODS: A retrospective evaluation of maternal and neonatal outcomes was performed for all consecutive pregnancies complicated by gestational or pregestational diabetes that happened between 2005 and 2011. Pregestational diabetes was diagnosed for the first time in pregnancy if the first-trimester fasting glycaemia was ≥126 mg/dL. Gestational diabetes was diagnosed according to Carpenter-Coustan criteria until May 2010, and then according to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) panel criteria modified by the American Diabetes Association. A specific diet, self-monitoring of blood glucose and, if required, insulin treatment were prescribed. RESULTS: Overall, 411 pregnant women were considered eligible for the study (379 with gestational diabetes and 32 with pregestational diabetes). Women with pregestational vs. gestational diabetes were diagnosed earlier in pregnancy (11.6±1.0 weeks vs. 25.9±1.7 weeks; P=0.0001), had a higher mean first-trimester fasting glycaemic level (129.5±3.6 mg/dL vs. 81.6±10.5mg/dL; P=0.0001), more often had a family history of diabetes (46.9% vs. 25.9%; P=0.02) and more often needed insulin treatment (78.1% vs. 14.0%; P=0.0001). Furthermore, a higher rate of fetal malformations in women with pregestational diabetes was detected (9.4% vs. 1.6%, P=0.02). No other differences in neonatal outcomes were identified. CONCLUSION: In a Caucasian population, the prevalence of fetal malformations and insulin requirements with pregestational diabetes first diagnosed in pregnancy were significantly higher compared with women with gestational diabetes. In any case, glucose impairment in pregnancy needs to be diagnosed in a timely fashion and appropriately treated to improve both maternal and fetal outcomes.


Subject(s)
Diabetes, Gestational/epidemiology , Pregnancy Outcome/epidemiology , Pregnancy in Diabetics/epidemiology , White People/statistics & numerical data , Adult , Female , Humans , Pregnancy , Retrospective Studies
11.
J Obstet Gynaecol ; 34(2): 123-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24456430

ABSTRACT

Gestational diabetes mellitus (GDM) is a condition of abnormal maternal glucose tolerance that occurs, or is detected, for the first time during pregnancy. The new diagnostic strategies recommend a 75 g, 2-h glucose tolerance test for all women not already known to be diabetic, in the early 3rd trimester of pregnancy. GDM is diagnosed when one or more values is equal to or exceeds the thresholds suggested (i.e. fasting ≥ 5.1 mmol/l, 1-h ≥ 10.0 mmol/l and 2-h ≥ 8.5 mmol/l). This criteria will determine a significant increase of the prevalence of GDM, primarily because only one abnormal value (OAV), not two, is sufficient to make the diagnosis. We also suppose that the new cases of gestational diabetes diagnosed with the new criteria will have an increased risk for subsequent abnormal glucose tolerance later in life, as it was largely confirmed in the past for the patients with two or more abnormal values.


Subject(s)
Diabetes, Gestational/diagnosis , Glucose Intolerance , Female , Glucose Tolerance Test , Humans , Pregnancy
12.
Osteoporos Int ; 25(3): 1123-9, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24114397

ABSTRACT

SUMMARY: Postmenopausal estrogen decline is implicated in several age-related physical and psychological changes in women, including decreases in perceived quality of life. The phytoestrogen genistein at a dose of 54 mg daily in osteopenic postmenopausal women after 2 years implies an improvement on quality of life and depression symptoms. INTRODUCTION: Postmenopausal estrogen decline is implicated in several age-related physical and psychological changes in women, including decreases in perceived quality of life (QoL). A number of trials with hormone therapy showed beneficial effects of the intervention on quality of life parameters. However, because of known or suspected serious side effects of conventional hormone therapy, there is a need for alternatives. METHODS: We conducted a double-blind randomized placebo-controlled trial using the isoflavone genistein, 54 mg, or placebo for 2 years. In this trial, we recruited 262 postmenopausal women aged 49 to 67 years. RESULTS: At baseline, after 1 year, and at final visit, participants filled in the Short Form of 36 questions (SF-36) and the Zung Self-rating Depression Scale (ZSDS). For the placebo group, scores on all dimensions of the SF-36 decreased after 1 and 2 years. The genistein group showed increases on all dimensions of the SF-36 at the end of the study. There were, however, statistically significant differences in changes of scores between the two intervention groups. For the ZSDS, similarly, significant differences were found between groups. CONCLUSION: In conclusion, the findings of this randomized trial showed that genistein improves quality of life (health status, life satisfaction, and depression) in osteopenic postmenopausal women.


Subject(s)
Bone Diseases, Metabolic/psychology , Depression/drug therapy , Genistein/therapeutic use , Phytoestrogens/therapeutic use , Quality of Life , Aged , Bone Density/drug effects , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/physiopathology , Depression/blood , Double-Blind Method , Estrogen Replacement Therapy , Female , Femur Neck/physiopathology , Genistein/blood , Humans , Lumbar Vertebrae/physiopathology , Middle Aged , Phytoestrogens/blood , Postmenopause/physiology , Postmenopause/psychology , Psychiatric Status Rating Scales , Psychometrics
13.
J Matern Fetal Neonatal Med ; 27(14): 1445-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24175881

ABSTRACT

There is a debate about whether universal or risk factors-based screening is most appropriate for gestational diabetes diagnosis. The aim of our retrospective study was to compare in our population the universal screening test recommended by the International Association of Diabetes in Pregnancy Study Group (IADPSG) panel and the American Diabetes Association (ADA) versus the selective screening proposed by the United Kingdom National Institute for Health and Clinical Excellence guidelines (NICE) but modified by the Italian National Institute of Health. From May 2010 to October 2011 all consecutive pregnant women were screened for gestational diabetes according to the IADPSG's panel criteria, while all the risk factors for each patient were registered. Of the 1015 pregnant women included in the study, 113 (11%) were diagnosed with gestational diabetes and 26 (23%) of them would not have been identified by the selective screening proposed by the Italian National Institute of Health. However, all the risk factors considered by the selective screening revealed a good predictive role except for maternal age ≥ 35 years (OR: 0.98). In the group without the risk factors considered, it was reported the predictive role for gestational diabetes of prepregnancy BMI and nulliparity. The selective risk factors-based screening proposed by the Italian National Institute of Health has detected 77% of gestational diabetes cases in our population, sparing the oral glucose tolerance test for more than 40% of pregnant women at the same time. More information on the clinical impact of this choice could be obtained by a strict analysis of treatment, perinatal outcome and follow-up of an adequate sample size of "missed" gestational diabetes.


Subject(s)
Diabetes, Gestational/epidemiology , Mass Screening , Prenatal Diagnosis , Adult , Female , Glucose Tolerance Test , Humans , Italy/epidemiology , Mass Screening/methods , Mass Screening/standards , Maternal Age , Practice Guidelines as Topic , Pregnancy , Prenatal Diagnosis/methods , Prenatal Diagnosis/standards , Retrospective Studies , Risk Factors , Young Adult
14.
J Diabetes Res ; 2013: 486593, 2013.
Article in English | MEDLINE | ID: mdl-24171177

ABSTRACT

OBJECTIVES: of this study were to assess diastolic function in pregnant women with abnormal glucose tolerance (AGT), compared with normal glucose tolerance (NGT) women, and to evaluate the insulin resistance status and its association with Doppler-echocardiographic indexes. Echocardiograms of 108 consecutive Caucasian women with singleton pregnancies were performed. Insulin resistance status was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI). All the studied women showed normal diastolic patterns. Patients with AGT (50.9%), as compared with NGT women, had higher HOMA-IR (1.70 ± 1.30 versus 1.01 ± 0.81, P = 0.003), lower QUICKI (0.36 ± 0.005 versus 0.40 ± 0.06, P = 0.004), higher lateral mitral annulus late diastolic velocity (13.6 ± 4.9 versus 11.9 ± 4.9, P = 0.03), and higher A-wave velocity, the wave responsible for the active atrial contraction component (75.2 ± 14.2 versus 67.7 ± 16.2, P = 0.01). At multivariate regression analysis HOMA-IR was the only parameter associated with A-wave velocity. In conclusion, women with AGT had an increased subclinical diastolic active participation, which is associated with higher levels of insulin resistance. For the increased risk of deterioration of cardiac diastolic function, earlier and more seriously than normal pregnancy, AGT women may have a careful followup to detect the early signs of cardiac alteration and to prevent cardiovascular diseases.


Subject(s)
Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/prevention & control , Diastole , Glucose Intolerance/complications , Glucose Intolerance/diagnostic imaging , Pregnancy Complications, Cardiovascular/diagnostic imaging , Prenatal Diagnosis/methods , Adult , Asymptomatic Diseases , Case-Control Studies , Early Diagnosis , Echocardiography, Doppler , Female , Glucose Tolerance Test , Humans , Pregnancy , Pregnancy Complications, Cardiovascular/prevention & control , Young Adult
15.
Diabetes Metab ; 38(5): 458-61, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22595470

ABSTRACT

AIM: To evaluate the correspondence between first-trimester fasting glycaemia and the results of the OGTT in diagnosing gestational diabetes (GDM). METHODS: The medical records of all consecutive women who had undergone a diagnostic OGTT, performed according to the IADPSG, during the past year were retrospectively reviewed. All first-trimester fasting glucose values greater or equal to 5.1 mmol/L (92 mg/dL), recommended as a diagnostic value, were also verified for each patient in this cohort. Moreover, a ROC curve and a multiple logistic-regression model were constructed to calculate the predictive capability of this cut-off value in diagnosing GDM. RESULTS: In our population of 738 eligible pregnant women, an 11.9% prevalence of GDM was revealed by OGTT. However, when the first-trimester fasting glucose value for each patient was retrospectively considered, there were a further 29 patients who should have been diagnosed as GDM cases (glycaemia ≥ 5.1 mmol/L), although their OGTT was normal. Yet, when the value of fasting glucose was considered not diagnostic, but only predictive, an AUC of 0.614 (95% CI: 0.544-0.684) and an aOR of 7.1 (95% CI: 3.8-13.1) was obtained in these patients compared with the reference group (fasting glucose < 5.1 mmol/L). CONCLUSION: There was no complete correspondence in diagnosing GDM between the first-trimester fasting glucose value and the results of a 2-h 75-g OGTT performed early in the third trimester. However, albeit not diagnostic, a fasting glucose value greater or equal to 5.1 mmol/L may be considered a highly predictive risk factor for GDM.


Subject(s)
Blood Glucose/metabolism , Diabetes, Gestational/diagnosis , Fasting , Glucose Tolerance Test , Glycated Hemoglobin/metabolism , Pregnancy Trimester, First , Adult , Diabetes, Gestational/blood , Diabetes, Gestational/epidemiology , Fasting/blood , Female , Humans , Italy/epidemiology , Logistic Models , Mass Screening , Practice Guidelines as Topic , Pregnancy , ROC Curve , Reference Values , Retrospective Studies
16.
J Obstet Gynaecol ; 32(2): 117-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22296417

ABSTRACT

To determine the institutional pregnancy complications rate associated with genetic amniocentesis and ascertain whether procedural variables or pre-existing factors may determine an increased risk of having a procedural-related fetal loss, we retrospectively evaluated all the consecutive amniocentesis, with known pregnancy outcome (n = 2990), performed between January 2001 and December 2009 by two very experienced clinicians. The patients who had counselling in the same period but declined to undergo amniocentesis represent the control group (n = 487). A total of 30 fetal losses occurred within 24 weeks' gestation (1%), while in the control group, we had four losses (0.8%). Procedural variables (transplacental sample, multiple needle insertions and gestational age) were not found to be predictive of increased fetal loss rate. Previous vaginal bleeding increased the risk of pregnancy loss after amniocentesis with an OR 4.1 (95% CI 2.0-8.7); on the contrary, a history of two or more miscarriages is not associated with a greater fetal loss rate, while the increased percentage (OR 3.4, 95% CI 1.2-9.0) in patients affected by uterine myoma appears connected, after the comparison with the control group, with the presence of fibroids rather than procedure.


Subject(s)
Amniocentesis/adverse effects , Pregnancy Outcome , Pregnancy Trimester, Second , Abortion, Spontaneous/etiology , Adult , Female , Fetal Membranes, Premature Rupture/etiology , Humans , Pregnancy , Premature Birth/etiology , Uterine Hemorrhage/etiology
17.
Diabetes Metab ; 38(1): 63-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21963427

ABSTRACT

AIM: The aim of this study was to determine the effects of maternal prepregnancy body mass index (BMI) and weight gain during pregnancy on perinatal outcome in non-diabetic women. METHODS: The clinical records of consecutive women who had undergone a glucose challenge test (GCT) and then delivered in our university hospital between January 2004 and December 2009 were retrospectively reviewed. Prepregnancy BMI and pregnancy weight gain were classified according to the US Institute of Medicine guidelines (1990). RESULTS: Of the eligible 2225 patients, obese and overweight women had a greater percentage of macrosomic babies (17.7% and 8.9%, respectively) compared with normal weight women (4.5%). However, when considered according to weight gain during pregnancy, the results were statistically significant only for excess weight gain in the obese (OR: 8.3, 95% CI: 2.4-28.4) and overweight (OR: 2.9, 95% CI: 1.2-6.8) groups. Also, the surgical delivery rate was significantly higher in the obese vs normal weight women (56% vs 36%, respectively) although, in this case, there was no difference according to normal and excess weight gain during pregnancy (OR: 1.4, 95% CI: 0.7-2.6). CONCLUSION: Overweight and obese women have an increased risk rate of macrosomia that can be limited by well-controlled weight gain during pregnancy. There was also a significantly higher rate of surgical delivery in the obese compared with the normal weight group that was, however, independent of excessive weight gain during pregnancy.


Subject(s)
Body Mass Index , Fetal Macrosomia/etiology , Obesity/complications , Pregnancy , Weight Gain , Adult , Female , Fetal Macrosomia/blood , Glucose Tolerance Test , Guidelines as Topic , Humans , Infant, Newborn , Obesity/blood , Pregnancy Complications/physiopathology , Pregnancy Outcome , Retrospective Studies , Risk Factors
18.
Climacteric ; 15(5): 490-5, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22192068

ABSTRACT

OBJECTIVE: To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome. METHODS: Eighty outpatient postmenopausal women, affected by metabolic syndrome, were enrolled in a 12-month study. All women were treated with a low-energy diet, and then they were randomly assigned to myo-inositol 2 g b.i.d. (n = 40) or placebo (n = 40). All the women were evaluated for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment. RESULTS: With the exception of BMI and waist circumference, after 12 months of treatment, all the parameters studied showed a significant improvement in the myo-inositol group compared to the control group. At the end of the study, in the myo-inositol group, the number of women without metabolic syndrome was eight (20%) whereas, in the control group, only one woman no longer had the metabolic syndrome after 12 months of diet. CONCLUSIONS: Myo-inositol might be considered one of the insulin-sensitizing substances in the treatment of metabolic syndrome.


Subject(s)
Inositol/therapeutic use , Metabolic Syndrome/drug therapy , Postmenopause , Blood Glucose/analysis , Blood Pressure , Body Mass Index , Caloric Restriction , Cholesterol, HDL/blood , Dietary Supplements , Female , Humans , Insulin/blood , Insulin Resistance , Metabolic Syndrome/blood , Middle Aged , Placebos , Triglycerides/blood , Waist Circumference
19.
Gynecol Endocrinol ; 28(6): 440-2, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22122627

ABSTRACT

To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome. A total of 98 pregnancies in PCOS women obtained in a 3-year period, either with myo-inositol (n. 54), or with metformin (n. 44) were considered. While myo-inositol was assumed through the whole pregnancy, the group of women treated with metformin stopped the drug assumption after pregnancy diagnosis, and was considered as a control group. After having eliminated cases of miscarriages and twin pregnancies, a definitive number of 46 women in the myo-inositol group and 37 in the control group was taken in account to be retrospectively evaluated. The primary outcome measure was GD occurrence in both groups; whereas secondary outcome measures were pregnancy outcomes: hypertensive disorders, pre-term birth, macrosomia and caesarean section occurrence. Prevalence of GD in the myo-inositol group was 17.4% versus 54% in the control group, with a highly significant difference also after adjusting for covariates. Consequently, in the control group the risk of GD occurrence was more than double compared to the myo-inositol group, with an odds ratio 2.4 (confidence interval 95%, 1.3-4.4). There was no difference between the groups in relation to secondary outcome measures. This study suggests a possible effect of myo-inositol in the primary prevention of GD in PCOS women.


Subject(s)
Diabetes, Gestational/prevention & control , Inositol/therapeutic use , Polycystic Ovary Syndrome/drug therapy , Adult , Diabetes, Gestational/epidemiology , Female , Humans , Hypoglycemic Agents/therapeutic use , Inositol/pharmacology , Metformin/therapeutic use , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/epidemiology , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/epidemiology , Pregnancy Outcome/epidemiology , Prevalence , Reproductive Techniques, Assisted , Retrospective Studies
20.
Diabet Med ; 28(8): 972-5, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21414183

ABSTRACT

AIM: To test the hypothesis that myoinositol supplementation will improve insulin sensitivity as measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance and adiponectin in women with gestational diabetes. METHODS: The trial was carried out in diet-treated patients with gestational diabetes diagnosed in our department between April 2008 and September 2009. Subjects were randomly assigned to receive either myoinositol supplementation (4 g daily) plus folic acid (400 µg daily)-the study group-or folic acid only (400 µg daily)-the control group. Both groups received the same diet prescription. Homeostasis model assessment of insulin resistance and adiponectin were assayed while fasting at the time of the diagnostic oral glucose tolerance test and after 8 weeks of treatment. RESULTS: There were 69 evaluable patients, 24 in the study group and 45 in the control group. Fasting glucose and insulin, and consequently homeostasis model assessment of insulin resistance, decreased in both groups (50% in the study group vs. 29% in the control group), but the decline in the study group was significantly greater than that in the control group (P = 0.0001). Adiponectin increased in the myoinositol group while it decreased in the control group (P = 0.009). CONCLUSION: Myoinositol improves insulin resistance in patients with gestational diabetes.


Subject(s)
Adiponectin/metabolism , Blood Glucose/drug effects , Diabetes, Gestational/drug therapy , Dietary Supplements , Inositol/therapeutic use , Insulin/metabolism , Adult , Blood Glucose/metabolism , Diabetes, Gestational/metabolism , Female , Glucose Tolerance Test , Humans , Hypoglycemic Agents , Inositol/metabolism , Insulin Resistance , Pregnancy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...